217 related articles for article (PubMed ID: 10208324)
1. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.
Nestby P; Schoffelmeer AN; Homberg JR; Wardeh G; De Vries TJ; Mulder AH; Vanderschuren LJ
Psychopharmacology (Berl); 1999 Mar; 142(3):309-17. PubMed ID: 10208324
[TBL] [Abstract][Full Text] [Related]
2. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.
Vanderschuren LJ; Schoffelmeer AN; Wardeh G; De Vries TJ
Psychopharmacology (Berl); 2000 May; 150(1):35-44. PubMed ID: 10867974
[TBL] [Abstract][Full Text] [Related]
3. Opioidergic modulation of ethanol self-administration in the ventral pallidum.
Kemppainen H; Raivio N; Suo-Yrjo V; Kiianmaa K
Alcohol Clin Exp Res; 2012 Feb; 36(2):286-93. PubMed ID: 21895714
[TBL] [Abstract][Full Text] [Related]
4. The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat.
Lindholm S; Werme M; Brené S; Franck J
Behav Brain Res; 2001 May; 120(2):137-46. PubMed ID: 11182162
[TBL] [Abstract][Full Text] [Related]
5. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress.
Matsuzawa S; Suzuki T; Misawa M; Nagase H
Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764
[TBL] [Abstract][Full Text] [Related]
6. Comparative hypotensive actions of three nonpeptide kappa opioid agonists on hippocampus of SHRs and normotensive WKY rats.
Zhai QZ; Ingenito AJ
J Cardiovasc Pharmacol; 1998 Jun; 31(6):806-12. PubMed ID: 9641463
[TBL] [Abstract][Full Text] [Related]
7. Opioids in the perifornical lateral hypothalamus suppress ethanol drinking.
Chen YW; Barson JR; Chen A; Hoebel BG; Leibowitz SF
Alcohol; 2013 Feb; 47(1):31-8. PubMed ID: 23199698
[TBL] [Abstract][Full Text] [Related]
8. Differential antagonism of the rate-decreasing effects of kappa-opioid receptor agonists by naltrexone and norbinaltorphimine.
Powell KR; Holtzman SG
Eur J Pharmacol; 1999 Jul; 377(1):21-8. PubMed ID: 10448921
[TBL] [Abstract][Full Text] [Related]
9. Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats.
Henderson-Redmond A; Czachowski C
Psychopharmacology (Berl); 2014 Nov; 231(22):4309-21. PubMed ID: 24770627
[TBL] [Abstract][Full Text] [Related]
10. Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice.
Kuzmin A; Sandin J; Terenius L; Ogren SO
J Pharmacol Exp Ther; 2000 Dec; 295(3):1031-42. PubMed ID: 11082438
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular responses to kappa opioid agonists in intact and adrenal demedullated rats.
Gulati A; Bhargava HN
Eur J Pharmacol; 1988 Nov; 156(2):247-57. PubMed ID: 2853675
[TBL] [Abstract][Full Text] [Related]
12. Effects of U50488 and bremazocine on [Ca2+]i and cAMP in naive and tolerant rat ventricular myocytes: evidence of kappa opioid receptor multiplicity in the heart.
Zhang WM; Wu S; Yu XC; Wang HX; Bian JS; Wong TM
J Mol Cell Cardiol; 1999 Feb; 31(2):355-62. PubMed ID: 10093048
[TBL] [Abstract][Full Text] [Related]
13. Bremazocine differentially antagonizes responses to selective mu and delta opioid receptor agonists in rat hippocampus.
Dunwiddie TV; Johnson KJ; Proctor WR
Br J Pharmacol; 1987 Jul; 91(3):523-30. PubMed ID: 3038241
[TBL] [Abstract][Full Text] [Related]
14. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.
Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
Neuroendocrinology; 1986; 42(1):82-7. PubMed ID: 3001566
[TBL] [Abstract][Full Text] [Related]
15. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
Craft RM; Dykstra LA
J Pharmacol Exp Ther; 1992 Jan; 260(1):334-42. PubMed ID: 1309877
[TBL] [Abstract][Full Text] [Related]
17. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
Craft RM; Dykstra LA
J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
[TBL] [Abstract][Full Text] [Related]
18. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
Ko MC; Johnson MD; Butelman ER; Willmont KJ; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1113-20. PubMed ID: 10565831
[TBL] [Abstract][Full Text] [Related]
19. Further study of kappa opioids on increased urination.
Leander JD
J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
[TBL] [Abstract][Full Text] [Related]
20. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
